Literature DB >> 17614969

Antibodies to selected minor target antigens in patients with anti-neutrophil cytoplasmic antibodies (ANCA).

M V Talor1, J H Stone, J Stebbing, J Barin, N R Rose, C L Burek.   

Abstract

In patients with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis, indirect immunofluorescence (IF) distinguishes between cytoplasmic (C-ANCA) and perinuclear (P-ANCA) neutrophil staining patterns. In patients with primary systemic vasculitis such as Wegener's granulomatosis, microscopic polyangiitis and Churg-Strauss syndrome, these IF staining patterns correspond broadly with antibodies to the two major antigens: the C-ANCA pattern is associated generally with antibodies to serine protease 3 (PR3) and the P-ANCA pattern with antibodies to myeloperoxidase (MPO). However, some sera positive for ANCA by IF are negative for anti-PR3 and anti-MPO antibodies, suggesting the presence of antibodies to minor antigens of PMN granules. We tested sera from a previously well-defined clinical cohort of patients for antibodies to four possible minor antigens: bactericidal permeability increasing protein, elastase, cathepsin G and lactoferrin. IF-positive (+) sera had significantly higher antibody frequencies to the minor antigens than did the IF-negative (-) sera (P < 0.01). Patients with IF(+) PR3(-)MPO(-) sera showed the most varied reactivity to the minor antigens. Among the IF(+) groups, the IF(+) PR3(+)/MPO(-) sera showed the lowest reactivity to the minor antigens. Patients with well-defined ANCA specificities, e.g. the PR3-ANCA response associated with Wegener's granulomatosis, are less likely than are other patient subsets to have antibodies to minor antigen targets. Autoantibodies to these minor antigens contribute to the overall pattern of ANCA identified by IF and help to explain why the correlation between IF and enzyme immunoassays show discrepancies. While the pathophysiological significance of antibodies to minor target antigens needs further evaluation, they may be markers of inflammation associated with disease processes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17614969      PMCID: PMC2219289          DOI: 10.1111/j.1365-2249.2007.03453.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

1.  Anti-cathepsin G antibodies in the sera of patients with ulcerative colitis.

Authors:  T Kuwana; Y Sato; M Saka; Y Kondo; M Miyata; K Obara; T Nishimaki; R Kasukawa
Journal:  J Gastroenterol       Date:  2000       Impact factor: 7.527

2.  Test characteristics of immunofluorescence and ELISA tests in 856 consecutive patients with possible ANCA-associated conditions.

Authors:  J H Stone; M Talor; J Stebbing; M L Uhlfelder; N R Rose; K A Carson; D B Hellmann; C L Burek
Journal:  Arthritis Care Res       Date:  2000-12

Review 3.  Antineutrophil cytoplasmic antibodies.

Authors:  G S Hoffman; U Specks
Journal:  Arthritis Rheum       Date:  1998-09

4.  Antineutrophil cytoplasmic antibody in patients with primary Sjögren's syndrome.

Authors:  K Nishiya; H Chikazawa; K Hashimoto; S Miyawaki
Journal:  Clin Rheumatol       Date:  1999       Impact factor: 2.980

5.  Autoantibodies and target antigens in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides.

Authors:  J A Savige; L Chang; D Wilson; R R Buchanan
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

6.  Endothelial tissue factor stimulation by proteinase 3 and elastase.

Authors:  M Haubitz; M Gerlach; H J Kruse; R Brunkhorst
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

7.  Anti-neutrophil cytoplasmic antibodies directed against the bactericidal/permeability-increasing protein (BPI) in pediatric cystic fibrosis patients do not recognize N-terminal regions important for the anti-microbial and lipopolysaccharide-binding activity of BPI.

Authors:  H Schultz; E Csernok; A Schuster; T S Schmitz; M Ernst; W L Gross
Journal:  Pediatr Allergy Immunol       Date:  2000-05       Impact factor: 6.377

8.  Anti-neutrophil cytoplasmic antibody (ANCA) in malaria is directed against cathepsin G.

Authors:  T M Yahya; S Benedict; A Shalabi; R Bayoumi
Journal:  Clin Exp Immunol       Date:  1997-10       Impact factor: 4.330

Review 9.  Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features.

Authors:  J Savige; D Davies; R J Falk; J C Jennette; A Wiik
Journal:  Kidney Int       Date:  2000-03       Impact factor: 10.612

10.  [Clinicopathological characteristics of propylthiouracil-induced antineutrophil cytoplasmic antibodies-positive vasculitis and their target antigens: a report of 4 cases and literature review].

Authors:  Xudong Xu; Minghui Zhao; Youkang Zhang; Xiaohui Guo; Haiyan Wang
Journal:  Zhonghua Nei Ke Za Zhi       Date:  2002-06
View more
  23 in total

Review 1.  Translational mini-review series on immunology of vascular disease: mechanisms of vascular inflammation and remodelling in systemic vasculitis.

Authors:  N Maugeri; P Rovere-Querini; M Baldini; M G Sabbadini; A A Manfredi
Journal:  Clin Exp Immunol       Date:  2009-03-20       Impact factor: 4.330

Review 2.  Laboratory investigation in the diagnosis of vasculitis.

Authors:  Luis Felipe Flores-Suárez
Journal:  Curr Rheumatol Rep       Date:  2009-12       Impact factor: 4.592

3.  Clinical implications of ANCA positivity in a hospital setting: a tertiary center experience.

Authors:  Bashar Fteiha; Alon Bnaya; Marwan Abu Sneineh; Gideon Nesher; Gabriel Simon Breuer
Journal:  Intern Emerg Med       Date:  2020-10-06       Impact factor: 3.397

Review 4.  ANCA-associated vasculitis with renal involvement.

Authors:  Valentina Binda; Gabriella Moroni; Piergiorgio Messa
Journal:  J Nephrol       Date:  2017-05-30       Impact factor: 3.902

Review 5.  ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients.

Authors:  Divi Cornec; Emilie Cornec-Le Gall; Fernando C Fervenza; Ulrich Specks
Journal:  Nat Rev Rheumatol       Date:  2016-07-28       Impact factor: 20.543

Review 6.  Antineutrophil cytoplasmic autoantibodies: how should the biologist manage them?

Authors:  C Beauvillain; Y Delneste; G Renier; P Jeannin; J F Subra; A Chevailler
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

Review 7.  An approach to the diagnosis and management of systemic vasculitis.

Authors:  A Miller; M Chan; A Wiik; S A Misbah; R A Luqmani
Journal:  Clin Exp Immunol       Date:  2010-01-12       Impact factor: 4.330

8.  p38MAPK, ERK and PI3K signaling pathways are involved in C5a-primed neutrophils for ANCA-mediated activation.

Authors:  Jian Hao; Li-Qiang Meng; Peng-Cheng Xu; Min Chen; Ming-Hui Zhao
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

9.  Automatic reading of ANCA-slides: evaluation of the AKLIDES system.

Authors:  Jan Damoiseaux; Kathleen Mallet; Mia Vaessen; Jos Austen; Jan Willem Cohen Tervaert
Journal:  Clin Dev Immunol       Date:  2012-11-05

10.  A pro-inflammatory role of C5L2 in C5a-primed neutrophils for ANCA-induced activation.

Authors:  Jian Hao; Chen Wang; Jun Yuan; Min Chen; Ming-Hui Zhao
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.